Zevra Therapeutics Statistics
Share Statistics
Zevra Therapeutics has 54.68M
shares outstanding. The number of shares has increased by 29.3%
in one year.
| Shares Outstanding | 54.68M |
| Shares Change (YoY) | 29.3% |
| Shares Change (QoQ) | 1.39% |
| Owned by Institutions (%) | 70.89% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 8 |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 5.92M, so 10.83% of the outstanding
shares have been sold short.
| Short Interest | 5.92M |
| Short % of Shares Out | 10.83% |
| Short % of Float | 10.9% |
| Short Ratio (days to cover) | 10.28 |
Valuation Ratios
The PE ratio is -3.66 and the forward
PE ratio is 11.34.
Zevra Therapeutics's PEG ratio is
-0.05.
| PE Ratio | -3.66 |
| Forward PE | 11.34 |
| PS Ratio | 16.34 |
| Forward PS | 1.1 |
| PB Ratio | 9.72 |
| P/FCF Ratio | -5.54 |
| PEG Ratio | -0.05 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Zevra Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.53,
with a Debt / Equity ratio of 1.52.
| Current Ratio | 2.53 |
| Quick Ratio | 2.47 |
| Debt / Equity | 1.52 |
| Debt / EBITDA | -0.79 |
| Debt / FCF | -0.87 |
| Interest Coverage | -11.84 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $400,203.39 |
| Profits Per Employee | $-1,788,322.03 |
| Employee Count | 59 |
| Asset Turnover | 0.13 |
| Inventory Turnover | 3.76 |
Taxes
| Income Tax | 15.37M |
| Effective Tax Rate | -17.05% |
Stock Price Statistics
The stock price has increased by 61.68% in the
last 52 weeks. The beta is 1.94, so Zevra Therapeutics's
price volatility has been higher than the market average.
| Beta | 1.94 |
| 52-Week Price Change | 61.68% |
| 50-Day Moving Average | 7.54 |
| 200-Day Moving Average | 7.81 |
| Relative Strength Index (RSI) | 57.63 |
| Average Volume (20 Days) | 447,181 |
Income Statement
In the last 12 months, Zevra Therapeutics had revenue of 23.61M
and earned -105.51M
in profits. Earnings per share was -2.28.
| Revenue | 23.61M |
| Gross Profit | 16.2M |
| Operating Income | -87M |
| Net Income | -105.51M |
| EBITDA | -76.4M |
| EBIT | -82.79M |
| Earnings Per Share (EPS) | -2.28 |
Full Income StatementBalance Sheet
The company has 33.78M in cash and 60.3M in
debt, giving a net cash position of -26.51M.
| Cash & Cash Equivalents | 33.78M |
| Total Debt | 60.3M |
| Net Cash | -26.51M |
| Retained Earnings | -505.29M |
| Total Assets | 178.13M |
| Working Capital | 51.96M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -69.67M
and capital expenditures 0, giving a free cash flow of -69.67M.
| Operating Cash Flow | -69.67M |
| Capital Expenditures | n/a |
| Free Cash Flow | -69.67M |
| FCF Per Share | -1.51 |
Full Cash Flow StatementMargins
Gross margin is 68.59%, with operating and profit margins of -368.47% and -446.85%.
| Gross Margin | 68.59% |
| Operating Margin | -368.47% |
| Pretax Margin | -381.76% |
| Profit Margin | -446.85% |
| EBITDA Margin | -323.56% |
| EBIT Margin | -368.47% |
| FCF Margin | -295.04% |
